Other Names | Activated Factor VII, Factor VIIa, Activated Recombinant Factor VII
---|---
Pre-Transfusion Sample | ✗ Not Required  ☐ Blood Group  ☐ Group & Screen  ☐ Crossmatch
Approval Requirements | Hematopathologist approval is required:
  • Prior to first time requests for NiaStase RT®
Product Description | NiaStase RT® contains activated recombinant coagulation Factor VII (rFVIIa).
  Available as a lyophilized powder in single use vials for reconstitution, using supplied histidine solvent, for injection.
  No latex is present in the vial closures.
  No human protein is used in the production or final formation.
  Supplied in 1.0 mg (50 KIU), 2.0 mg (100 KIU) and 5.0 mg (250 KIU) vials. When reconstituted, the final concentration is 1 mg/mL.
  Note: KIU = kilo-international units.
  Reconstituted in Transfusion Medicine and issued in a syringe.
Clinical Indications | • Hemophilia A / B patients with inhibitors to Factor VIII or Factor IX for the treatment of bleeding episodes.
  • Patients with severe hereditary Factor VII deficiency.
Contraindications | • Patients with known hypersensitivity to NiaStase RT® or any of its components.
  • Patients with sensitivity to mouse, hamster or bovine proteins.
Risks | Pyrexia, injection site reaction, headache, hypertension, hypotension, nausea, vomiting, pain, edema and rash, allergic reactions and anaphylaxis.
  Formation of anti-Factor VII antibodies.
  Thrombotic events are a potential risk in patients with DIC, advanced atherosclerosis, crush injury, septicemia or treatment with prothrombin complexes.
Dosage | All Hemophilia patients carry a Factor First card with pertinent information about their prescribed therapy.
  
  **Dose range:** 35–120 µg/kg
  
  **Recommended dose:** 90 µg/kg
  Dose may vary depending on severity of bleeding or surgery type.
  Consult with the Hematologist-on-call or Bleeding Disorders Clinic Nurse Practitioner for dosing and prescribing guidelines.
Administration | Visually inspect for particulate matter and discolouration prior to administration
  Refer to:
  • Administering Medications Using IV Push Method
### Product monograph

**Administer:**
- By intravenous injection only
- At room temperature
- Through a separate injection site
- Inject intravenously over several minutes. The rate of administration should be determined by patient’s comfort level.
- Must not be filtered.

### Compatible Solution

The manufacturer does not recommend any compatible fluids.

**Flush** the line before and after administration with 0.9% Normal Saline only.

**Do not** mix with other medicinal products or intravenous admixtures.

### Infusion Rates

No mL per minute rate given by manufacturer.

**Inject** intravenously over several minutes. The rate of administration should be determined by patient’s comfort level.

### Monitoring

**Observe** patient for signs and symptoms of a transfusion reaction.

In the event of a suspected transfusion reaction, **refer** to Transfusion Reaction Procedure & Quick Reference guide and **complete** Transfusion Reaction Report Form.

**Monitor** closely for signs and symptoms of thrombosis. The dosage may need to be reduced or treatment stopped depending on patient’s symptoms.

**Evaluate** effectiveness of treatment.

### Storage Conditions

Stored at room temperature which should not exceed 30˚C.

Home storage of NiaStase RT may vary from in hospital storage and does not apply in the hospital situation.

For reconstituted product:
- Store at room temperature.
- Administer within 3 hours of reconstitution.
- Return product and Transfusion Record to Transfusion Medicine within 20 minutes from time of issue if there are any delays in administration.
- Do not refrigerate or store on nursing unit.

### References


Retrieved from: [http://novonordisk.ca/PDF_Files/our_products/NiaStaseRT/NiaStaseRTPM.pdf](http://novonordisk.ca/PDF_Files/our_products/NiaStaseRT/NiaStaseRTPM.pdf)